King's College London

Research portal

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Research output: Contribution to journalLetterpeer-review

Guillermo Garcia-Manero, Ghulam J. Mufti, Pierre Fenaux, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Osman Ilhan, Mikkael A. Sekeres, Amer M. Zeidan, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Jay T. Backstrom, Uwe Platzbecker, Rami S. Komrokji

Original languageEnglish
Pages (from-to)624-629
Number of pages6
JournalBlood
Volume139
Issue number4
DOIs
Published27 Jan 2022

Bibliographical note

Funding Information: This study was sponsored by Celgene, a Bristol Myers Squibb Company, Princeton, New Jersey in collaboration with Acceleron Pharma. The authors received writing support in the preparation of this report from Karolina Lech of Excerpta Medica, supported by Bristol Myers Squibb.

King's Authors

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454